With increasing number of therapies available for the treatment of multiple myeloma, it is
timely to examine the course of patients' journeys. We investigated patient characteristics, …

Real‐world data describing management of patients with multiple myeloma are limited. A
European (Belgium, France, Germany, Italy, Spain, Switzerland, UK ) observational chart …

… To our knowledge, there is no validated severity grading system that predicts clinical
outcome in SSTIs, along the lines of that for community-acquired pneumonia. There …

… is a primary objective of treatment, it is also important to consider the impact of treatment on
patients’ quality of life while receiving therapy as well as the potential for treatment toxicity to …

Registry data are important for monitoring the impact of new therapies on treatment algorithms
and outcomes, and for guiding clinical decision making in multiple myeloma (MM). This …

… , Janssen and Takeda; L Fink is an employee of Kantar Health, which received funding
from Amgen to conduct this research; S Gonzalez-McQuire is an Amgen employee and holds …

… We anticipate that the model is most likely to be used when treatment is shown to affect a
combination of the disease progression attributes of exacerbations, lung function, exercise …

Background. To develop statistical models predicting disease progression and outcomes in
chronic obstructive pulmonary disease (COPD), using data from ECLIPSE, a large, …

… S Gonzalez-McQuire is an employee of Amgen (Europe) GmbH and stockholder of Amgen
Inc. Z Szabo is an employee of Amgen (Europe) GmbH and stockholder of Amgen Inc. P …

… Delphi methodology is a recognized method for gaining expert consensus and has been
used extensively across the social sciences. It is useful for gaining the input of a variety of …